home / stock / immp / immp news

IMMP News and Press, Immutep Limited From 11/02/22

Stock Information
Company Name: Immutep Limited
Stock Symbol: IMMP
Market: NASDAQ
Website: immutep.com
Menu
IMMP IMMP Quote IMMP Short IMMP News IMMP Articles IMMP Message Board
Get IMMP Alerts

News, Short Squeeze, Breakout and More Instantly...
IMMP - Immutep Late-Breaking Abstract Accepted for Oral Presentation on First-in-Class LAG-3 Therapeutic Eftilagimod Alpha at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting

Media Release SYDNEY, AUSTRALIA, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, tod...
IMMP - Immutep Announces Independent Data Monitoring Committee Positive Recommendation to Continue TACTI-003 Trial as Planned

Media Release SYDNEY, AUSTRALIA, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today...

IMMP - Immutep Announces Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting

SYDNEY, AUSTRALIA, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease, will announce first ...

IMMP - Immutep stock climbs on FDA fast track status for eftilagimod to treat lung cancer subtype

The U.S. Food and Drug Administration (FDA) granted fast track designation to Immutep's ( NASDAQ: IMMP ) eftilagimod alpha (IMP321) in combination with Merck's ( NYSE: MRK ) Keytruda (pembrolizumab) to treat first line non-small cell lung cancer (NSCLC). The co...
IMMP - Immutep Receives FDA Fast Track Designation for LAG-3 Therapeutic Eftilagimod Alpha for First Line Non-Small Cell Lung Cancer

Fast Track designation has been granted by the US FDA for efti in combination with pembrolizumab in 1 st line non-small cell lung cancer Based on the encouraging Phase II clinical data for PD-L1 all-comers presented at ASCO 2022 Marks the second Fast Track designation issued b...

IMMP - Immutep (IMMP) presents at Non-Small Cell Lung Cancer (NSCLC) Drug Development Summit - Slideshow

The following slide deck was published by Immutep Limited in conjunction with this event. For further details see: Immutep (IMMP) presents at Non-Small Cell Lung Cancer (NSCLC) Drug Development Summit - Slideshow

IMMP - Immutep to Participate in Two Upcoming Investor Conferences

SYDNEY, AUSTRALIA, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease, today announced that Marc ...
IMMP - Immutep secures Euro1.8M cash in French government's research tax credit

Immutep ( NASDAQ: IMMP ) announced Friday it has received €1.8M cash from the French government in research and development tax incentive payment. The incentive comes under the government's research tax credit scheme under which French companies conducting...

IMMP - Immutep Receives A$2.7 million R&D Tax Incentive from French Government

SYDNEY, AUSTRALIA, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune diseases, is pleased to ann...

IMMP - Immutep Clinical Development Update for its First-in-Class LAG-3 Antigen Presenting Cell Activator Candidate Eftilagimod Alpha

Encouraging Phase II data supports broad therapeutic potential of eftilagimod alpha in non-small cell lung cancer (NSCLC), head & neck squamous cell cancer (HNSCC) and metastatic breast cancer (MBC) Planning and regulatory interactions ongoing with a focus now prioritising 1 st ...
Previous 10 Next 10